Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

Researchers produce lightweight grab-poles with anti-microbial property for public transport

Since the beginning of the Covid-19 pandemic many people have been, or may feel, hesitant about taking public transport, due to the perceived risk of picking up germs from areas such as the grab-poles on trains, buses and trams, which are the principal point of contact.

13 Jan 2021

Health workers unions see surge in interest amid covid

The nurses at Mission Hospital in Asheville, North Carolina, declared on March 6 — by filing the official paperwork — that they were ready to vote on the prospect of joining a national union. At the time, they were motivated by the desire for more nurses and support staff, and to have a voice in hospital decisions.

12 Jan 2021

OXGENE introduces SLIM platform for discovery of antibodies against membrane proteins

OXGENE™ announces the introduction of its self-labelling integral membrane (SLIM™) protein discovery system.

12 Jan 2021

Rice model could help clinicians personalize hip joints

Rice University engineers hope to make life better for those with replacement joints by modeling how artificial hips are likely to rub them the wrong way.

11 Jan 2021

Researchers identify bacterium that produces pharmaceutical all-purpose weapon

For some years, an active substance from the leaves of an ornamental plant has been regarded as a possible forerunner of a new group of potent drugs. So far, however, it has been very laborious to manufacture it in large quantities.

11 Jan 2021

Researchers receive NIH grant to develop more effective flu vaccines

To build better vaccines, scientists want to know more about how our bodies make adequate numbers of effective, durable antibodies against the influenza virus.

11 Jan 2021

Advanced nanomaterial-based biosensing platform rapidly detects COVID-19 antibodies

Researchers at Carnegie Mellon University report findings on an advanced nanomaterial-based biosensing platform that detects, within seconds, antibodies specific to SARS-CoV-2, the virus responsible for the COVID-19 pandemic.

8 Jan 2021

RedHill Biopharma: RHB-204 receives FDA Fast Track designation for treatment of NTM disease

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that RHB-204 has been granted Fast Track designation by the U.S. Food and Drug Administration for its development as a potential first-line, stand-alone, oral treatment of pulmonary nontuberculous mycobacteria (NTM) disease caused by Mycobacterium avium Complex (MAC) - a rare disease for which there is no FDA-approved first-line therapy.

6 Jan 2021

Researchers receive £230,000 to develop world's first smart vaccine device

Researchers at Swansea University have received £230,000 to develop the world's first smart vaccine device that will both deliver the COVID-19 vaccine and measure its efficacy through monitoring the body's associated response.

6 Jan 2021

UC-MSC infusions reduce risk of death, quicken recovery time in severe COVID-19 cases

Dr. Camilo Ricordi, director of the Diabetes Research Institute and Cell Transplant Center at the University of Miami Miller School of Medicine, and his team of international collaborators are reporting the results of a groundbreaking randomized controlled trial showing umbilical cord-derived mesenchymal stem cell (UC-MSC) infusions safely reduce risk of death and quicken time to recovery for the most severe COVID-19 patients.

5 Jan 2021

P2 COVID-19 study shows no material safety differences between opaganib and control arms

Preliminary data from the non-powered U.S. Phase 2 study of 40 hospitalized patients shows that orally-administered opaganib was safe, with no material safety differences between opaganib and control arms.

4 Jan 2021

Phase 3 trial of Novavax COVID-19 vaccine candidate begins enrolling volunteers

The Phase 3 trial of another investigational coronavirus disease 2019 (COVID-19) vaccine has begun enrolling adult volunteers.

28 Dec 2020

Many lighter smokers can be addicted to cigarettes

Even people who consider themselves to be casual cigarette smokers may be addicted, according to current diagnostic criteria.

23 Dec 2020

Phase 2/3 COVID-19 study evaluates safety, potential identification of preliminary efficacy signals

Top-line data from the 270-patient global Phase 2/3 COVID-19 study expected Q1/2021. Top-line data from the 40-patient U.S. Phase 2 study of opaganib in severe COVID-19 expected in the coming days; this non-powered study was designed to evaluate safety and potential identification of preliminary efficacy signals in support of the global Phase 2/3 study of opaganib.

23 Dec 2020

FDA issues warning letters to companies illegally selling unapproved CBD products

Today, the U.S. Food and Drug Administration issued five warning letters to companies for selling products containing cannabidiol (CBD) in ways that violate the Federal Food, Drug, and Cosmetic Act (FD&C Act).

22 Dec 2020

Cadmium linked to more severe flu and pneumonia infections

In this interview, News-Medical speaks to Dr. Howard Hu about his latest research into cadmium and how it could be causing more severe pneumonia infections.

22 Dec 2020

Many US health experts underestimated the coronavirus … until it was too late

A year ago, while many Americans were finishing their holiday shopping and finalizing travel plans, doctors in Wuhan, China, were battling a mysterious outbreak of pneumonia with no known cause.

21 Dec 2020

FDA issues first emergency use authorization for second COVID-19 vaccine

Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the second vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

21 Dec 2020

Novel SARS-CoV-2 neutralizing antibody enters Phase 1/2a clinical study

Cologne University Hospital (UKK), University of Marburg (UMR), the German Center for Infection Research (DZIF) and Boehringer Ingelheim today announced the initiation of Phase 1/2a clinical investigation of BI 767551, a new SARS-CoV-2 neutralizing antibody.

18 Dec 2020

Study: At least a fifth of the world’s population may not have access to covid-19 vaccine until 2022

Nearly a quarter of the world’s population may not have access to a covid-19 vaccine until at least 2022, warns a study published by The BMJ today.

18 Dec 2020

Manufacturing News and Research

Further Reading

Researchers produce lightweight grab-poles with anti-microbial property for public transport

Health workers unions see surge in interest amid covid

OXGENE introduces SLIM platform for discovery of antibodies against membrane proteins

Rice model could help clinicians personalize hip joints

Researchers identify bacterium that produces pharmaceutical all-purpose weapon

Researchers receive NIH grant to develop more effective flu vaccines

Advanced nanomaterial-based biosensing platform rapidly detects COVID-19 antibodies

RedHill Biopharma: RHB-204 receives FDA Fast Track designation for treatment of NTM disease

Researchers receive £230,000 to develop world's first smart vaccine device

UC-MSC infusions reduce risk of death, quicken recovery time in severe COVID-19 cases

P2 COVID-19 study shows no material safety differences between opaganib and control arms

Phase 3 trial of Novavax COVID-19 vaccine candidate begins enrolling volunteers

Many lighter smokers can be addicted to cigarettes

Phase 2/3 COVID-19 study evaluates safety, potential identification of preliminary efficacy signals

FDA issues warning letters to companies illegally selling unapproved CBD products

Cadmium linked to more severe flu and pneumonia infections

Many US health experts underestimated the coronavirus … until it was too late

FDA issues first emergency use authorization for second COVID-19 vaccine

Novel SARS-CoV-2 neutralizing antibody enters Phase 1/2a clinical study

Study: At least a fifth of the world’s population may not have access to covid-19 vaccine until 2022

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®